Benzothiazinone analogs as Anti-Mycobacterium tuberculosis DprE1 irreversible inhibitors: Covalent docking, validation, and molecular dynamics simulations
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0314422 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Mahmoud A A Ibrahim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Science, Chemistry Department, Computational Chemistry Laboratory, Minia University, Minia, Egypt. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Molecular Docking Simulation, Antitubercular Agents, Molecular Dynamics Simulation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mycobacterium tuberculosis is a lethal human pathogen, with the key flavoenzyme for catalyzing bacterial cell-wall biosynthesis, decaprenylphosphoryl-D-ribose oxidase (DprE1), considered an Achilles heal for tuberculosis (TB) progression. Inhibition of DprE1 blocks cell wall biosynthesis and is a highly promising antitubercular target. Macozinone (PBTZ169, a benzothiazinone (BTZ) derivative) is an irreversible DprE1 inhibitor that has attracted considerable attention because it exhibits an additive activity when combined with other anti-TB drugs. Herein, 754 BTZ analogs were assembled in a virtual library and evaluated against the DprE1 target using a covalent docking approach. After validation of the employed covalent docking approach, BTZ analogs were screened. Analogs with a docking score less than –9.0 kcal/mol were advanced for molecular dynamics (MD) simulations, followed by binding energy evaluations utilizing the MM-GBSA approach. Three BTZ analogs–namely, PubChem-155-924-621, PubChem-127-032-794, and PubChem-155-923-972– exhibited higher binding affinities against DprE1 compared to PBTZ169 with Δ G binding values of –77.2, –74.3, and –65.4 kcal/mol, versus –49.8 kcal/mol, respectively. Structural and energetical analyses were performed for the identified analogs against DprE1 throughout the 100 ns MD simulations, and the results demonstrated the great stability of the identified BTZ analogs. Physicochemical and ADMET characteristics indicated the oral bioavailability of the identified BTZ analogs. The obtained in-silico results provide promising anti-TB inhibitors that are worth being subjected to in-vitro and in-vivo investigations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Science, Chemistry Department, Computational Chemistry Laboratory, Minia University, Minia, Egypt.
- School of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban, South Africa.
- Department of Chemistry, The American University in Cairo, New Cairo, Egypt.
- Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia.
- Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Tanta University, Tanta, Egypt.
- Department of Chemistry & Biochemistry, Texas Tech University, Lubbock, TX, United States of America.
ORCID-Profile: Mahmoud A A Ibrahim, Khlood A A Abdeljawaad, Paul W Paré
Zitieren
APA
Ibrahim, M. A. A., Mahmoud, D. G. M., Abdelrahman, A. H. M., Abdeljawaad, K. A. A., Mekhemer, G. A. H., Shoeib, T., El-Tayeb, M. A., Sidhom, P. A., Paré, P. W., & Hegazy, M. F. (2024). Benzothiazinone analogs as Anti-Mycobacterium tuberculosis DprE1 irreversible inhibitors: Covalent docking, validation, and molecular dynamics simulations. PLOS ONE. https://doi.org/10.1371/journal.pone.0314422
Vancouver
Ibrahim MAA, Mahmoud DGM, Abdelrahman AHM, Abdeljawaad KAA, Mekhemer GAH, Shoeib T, et al. Benzothiazinone analogs as Anti-Mycobacterium tuberculosis DprE1 irreversible inhibitors: Covalent docking, validation, and molecular dynamics simulations. PLOS ONE. 2024. doi:10.1371/journal.pone.0314422
BibTeX
@article{Ibrahim2024,
author = {Ibrahim, Mahmoud A A and Mahmoud, Doaa G M and Abdelrahman, Alaa H M and Abdeljawaad, Khlood A A and Mekhemer, Gamal A H and Shoeib, Tamer and El-Tayeb, Mohamed A and Sidhom, Peter A and Paré, Paul W and Hegazy, Mohamed-Elamir F},
title = {Benzothiazinone analogs as Anti-Mycobacterium tuberculosis DprE1 irreversible inhibitors: Covalent docking, validation, and molecular dynamics simulations},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0314422}
}
EUVIMED